How Long Does the Pneumonia Vaccine Last?

Protection from pneumonia vaccines generally lasts several years, but exactly how long depends on the type of vaccine you received. The older polysaccharide vaccine (PPSV23) keeps antibody levels elevated for roughly five to ten years, while the newer conjugate vaccines (PCV13, PCV15, PCV20) have demonstrated effectiveness for at least four to five years, with their immune memory mechanism suggesting protection persists even longer. The distinction between these vaccine types matters more than most people realize, because they train your immune system in fundamentally different ways.

Two Vaccine Types, Two Immune Strategies

There are two basic kinds of pneumococcal vaccine, and they work differently at the immune level. The polysaccharide vaccine (PPSV23) presents sugar molecules from the surface of 23 pneumococcal strains to your immune system. Your body makes antibodies against those sugars, but the response largely skips the step where it builds long-term immune memory. Think of it as a temporary alarm system that rings loudly at first but gradually fades.

Conjugate vaccines (the PCV family) attach those same sugar molecules to a carrier protein. That protein acts as a signal flare for a deeper arm of your immune system, triggering the creation of memory B cells that stick around and can ramp up antibody production quickly if you encounter the bacteria later. Research confirms this distinction: conjugate vaccines prompt the body to produce these memory cells, whereas the polysaccharide vaccine does not.¹ That difference in immune training is what shapes how long each vaccine’s protection holds up.

How Long PPSV23 Lasts

After a dose of PPSV23, your antibody levels climb quickly and then start a slow decline. Across most studies, those antibody levels remain above what you would see in unvaccinated adults for at least five to ten years.² That is a meaningful window, but it is not permanent. The exceptions tend to be people who are frail, non-ambulatory, or who have health conditions that compromise their immune function. In those groups, antibodies can drop off more quickly.

Revaccination five to ten years after the first dose does boost antibody levels substantially.² This is why, under previous guidelines, a second dose of PPSV23 was recommended for people at high risk. However, the polysaccharide vaccine has a quirk that complicates repeated dosing, which we will return to below.

How Long Conjugate Vaccines Last

The best direct evidence for conjugate vaccine duration in adults comes from the CAPiTA trial, a large study of PCV13 in older adults. That trial showed PCV13 maintained its effectiveness against vaccine-type pneumonia that did not involve the bloodstream (about 45% effectiveness) and against invasive pneumococcal disease (about 75%) for at least four to five years after vaccination.³ And “at least” is the key phrase: the trial ended at that point, so we know the floor, not the ceiling.

For the newer conjugate vaccines, PCV15 and PCV20, no similarly large effectiveness trial has been run. What we have instead are immunogenicity studies showing that the antibody responses to PCV15 and PCV20 are comparable to or better than PCV13 shortly after vaccination. Since these vaccines use the same conjugate technology, their duration is expected to mirror PCV13, meaning several years of meaningful protection.³ The confidence in that projection is reasonable, but real-world data on decade-long durability simply do not exist yet for PCV20.

Why “How Long” Is Hard to Pin Down

One reason you will not find a clean expiration date for any pneumonia vaccine is that there is no single antibody level that neatly separates “protected” from “unprotected.” The World Health Organization set a reference antibody concentration of 0.35 micrograms per milliliter as a benchmark for licensing conjugate vaccines against invasive pneumococcal disease in children.⁴ But that threshold was designed for population-level regulatory decisions, not for predicting whether any one person is still protected.

The actual level of antibody you need to stay safe varies depending on the specific pneumococcal strain, the type of infection (bloodstream invasion versus pneumonia versus ear infection), and your age and immune health. Preventing pneumonia in the lungs, for example, likely requires higher antibody levels than preventing bloodstream infection.⁵ This is why two people with the same antibody level on a blood test could have very different real-world protection. It also means that “five to ten years” is a broad average, not a precise timer ticking down identically in everyone.

When Protection Fades Faster

People on immunosuppressive medications can lose vaccine-induced protection far sooner than the general estimates suggest. In a study of patients with established arthritis receiving different antirheumatic drugs, antibody levels after a conjugate pneumococcal vaccine climbed initially but then dropped back to pre-vaccination levels within a year and a half.⁶ Methotrexate and anti-TNF therapy were particularly associated with poor antibody persistence among those patients. The researchers suggested that earlier revaccination with a conjugate vaccine might be necessary for people on potent immunosuppressive treatment.⁶

This extends beyond arthritis patients. People who have had organ transplants, who are on chemotherapy, who have HIV, or who take other drugs that suppress immune function should assume their protection window is shorter. If you fall into any of these groups, your doctor may recommend revaccination on a tighter schedule than the general population follows. The general five-to-ten-year estimates were largely derived from studies of otherwise healthy adults, so they overestimate durability for people with weakened immune systems.

How Long Vaccine Protection Lasts in Children

Children follow a different vaccination schedule from adults, typically receiving a series of conjugate vaccine doses in infancy with a booster around twelve to fifteen months. The good news is that even a single toddler dose of PCV13 appears to establish enough immune memory for the additional serotypes it covers. In a follow-on study of children who had received various combinations of earlier conjugate vaccines, antibody levels for PCV13-specific strains persisted at least two years after the toddler dose, and when these children received another dose of PCV13, they mounted a rapid, robust antibody response, a hallmark of functioning immune memory.⁷

This rapid recall response is the key difference between conjugate and polysaccharide vaccines. Even when antibody levels measurably decline in children after conjugate vaccination, the underlying memory cells remain. Encounter the bacterium (or a booster dose), and those cells spring into action. It is why children who complete the recommended series are generally considered well protected through early childhood without needing additional pneumococcal doses until adulthood, barring specific medical conditions that warrant earlier revaccination.

The Polysaccharide Revaccination Problem

If antibody levels from PPSV23 fade after several years, the obvious solution seems to be getting another dose. But repeated doses of polysaccharide vaccine come with a catch called hyporesponsiveness. In a study of children given the polysaccharide vaccine at twelve months of age, those who had received a prior dose responded less well to a repeat polysaccharide challenge. Across all 23 serotypes tested, prior exposure to the polysaccharide vaccine was associated with a lower antibody response to the subsequent dose compared to children who had never received it.⁸

In plain terms, the polysaccharide vaccine can partially exhaust the pool of immune cells that respond to those sugar antigens, so when you give the same stimulus again, the response is blunted rather than boosted. This is one of the reasons current guidelines have shifted toward conjugate vaccines as the primary recommendation for adults. Conjugate vaccines, by engaging a different arm of the immune system and generating true memory cells, do not produce this dampening effect and can actually “prime” the immune system for a stronger response to subsequent doses.

If you were previously vaccinated with PPSV23 and are now being offered a conjugate vaccine, the usual recommendation is to wait at least a year between the polysaccharide dose and a conjugate dose. This spacing allows the immune system to recover from the blunting effect.

Serotype Replacement and the Shifting Target

Even when your vaccine-induced antibodies are still circulating at healthy levels, the protection they offer can be undermined by something happening at the population level: serotype replacement. Pneumococcal vaccines target a specific set of the more than 90 known pneumococcal strains. When those targeted strains are suppressed by widespread vaccination, strains not covered by the vaccine can fill the ecological gap.

This phenomenon has been documented repeatedly. After the introduction of PCV7, which targeted seven strains, the prevalence of non-vaccine strains increased substantially among people carrying the bacteria asymptomatically. Disease caused by those non-vaccine strains also increased, though in most populations the increase was smaller than the overall benefit the vaccine provided.⁹ The same pattern has continued with PCV13. In a study from Tanzania, vaccine-type strains dropped from 55% of pneumococcal isolates before PCV13 introduction to about 23% after, and 14 non-vaccine strains emerged that had not been detected before.¹⁰

A striking example played out in New Zealand. When the country switched from PCV13 back to PCV10 (which does not cover serotype 19A), serotype 19A surged to account for 33% of all invasive pneumococcal disease cases by 2022, up from 18% in 2014. Among children under five, 19A rose from 31% to 59% of cases over the same period.¹¹ The vaccine was still “lasting” in the sense that antibodies against its covered strains persisted, but the disease landscape had shifted underneath it. This is part of the rationale behind the move to broader vaccines like PCV20, which covers 20 strains.

Herd Protection and What It Means for Adults

If you are an older adult, some of your protection against pneumococcal disease does not come from your own vaccination at all. When children are widely vaccinated with conjugate vaccines, they carry fewer pneumococcal bacteria in their noses and throats, which means they transmit less of it to the adults around them. This indirect or “herd” effect has been a significant contributor to declining pneumococcal disease rates among older adults in many countries.

However, this indirect protection is uneven. A systematic review found that the herd effect on older populations depends heavily on how high childhood vaccination coverage is and how long the vaccine program has been running.¹² In some countries, including Italy, vaccine-targeted strains still caused most pneumonia and invasive disease in elderly adults even after years of childhood immunization programs.¹³ The takeaway is that relying on herd protection alone is not enough. Adults in the recommended age groups benefit from direct vaccination regardless of how good the childhood program is where they live.

Pairing With the Flu Shot

Influenza and pneumococcal disease have a nasty synergy. The flu damages the lining of the respiratory tract and suppresses local immune defenses, making it far easier for pneumococcal bacteria to invade. This is why pneumococcal pneumonia is a common and dangerous complication of influenza. Getting both vaccines is recommended because their benefits are complementary: the combined effect is greater than either vaccine alone.¹⁴

There is an important caveat, though. Even with good pneumococcal vaccination, bacterial pneumonia following influenza can be harder to fight off. Animal research has shown that after influenza infection, the immune system’s ability to clear pneumococcal bacteria from the lungs is substantially weakened, with vaccinated animals showing only modest bacterial clearance during co-infection.¹⁵ This does not mean pneumococcal vaccination is useless during flu season. It means that preventing the flu in the first place, through influenza vaccination, is itself a way to help your pneumococcal immunity do its job effectively.

Broader Vaccines and Future Directions

The pneumococcal vaccine landscape is expanding. PCV20, which covers 20 strains, is now a standard recommendation for adults in many countries. PCV21, an even newer formulation covering a different and partly overlapping set of 21 strains, is being evaluated. Cost-effectiveness analyses have already modeled how PCV21 performs against PPSV23, PCV15, and PCV20 in previously vaccinated adults aged 65 and older, examining scenarios where prior vaccination occurred five or eight years ago.¹⁶ As the time since prior vaccination increases, the case for revaccination with a broader conjugate vaccine generally strengthens.

An intriguing finding has also emerged from pediatric research: conjugate pneumococcal vaccines may offer some protection beyond pneumococcal disease. In a population-based study of infants, receiving at least three doses of a conjugate pneumococcal vaccine was associated with a roughly 21% reduction in hospitalizations for respiratory syncytial virus (RSV) among non-Aboriginal infants.¹⁷ The mechanism likely involves reduced bacterial co-infection complicating RSV illness rather than direct antiviral activity, but it underscores how removing pneumococcal bacteria from the picture has ripple effects on respiratory health more broadly. Whether similar cross-protective benefits hold in adults is not yet established, but the finding hints at benefits that go beyond what the vaccine’s label promises.